How Rosén was paid
$671,407 in total for 2025, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.
Named executive officers
| Executive | Salary | Bonus | Options | Other | Total |
|---|---|---|---|---|---|
| Christer RosénChairman of the Board and Chief Executive Officer | $441,000 | $210,000 | — | $20,407 | $671,407 |
| Saleem ElmasriChief Financial Officer | $240,000 | $72,000 | $102,128 | — | $414,128 |
| Marshall HaywardChief Scientific Officer | $176,400 | $50,000 | — | $16,145 | $242,445 |
| Alexander RosénChief Administration Officer | $252,000 | $72,000 | — | $15,665 | $339,665 |
| Alison SilvaChief Business Officer and President | $315,000 | $45,000 | $255,320 | $16,779 | $632,099 |
What changed and why
- $671K$671,407 was CEO Christer Rosén’s 2025 total compensation, versus $154,076 in 2024.
- $210K$210,000 was Rosén’s 2025 bonus, compared with no bonus reported for 2024.
- 255,320 stock options were awarded to Alison Silva, and 102,128 to Saleem Elmasri, for IPO-related contributions.
- $1.19$1.19 was the exercise price of the 2025 IPO-related stock options.
- 30%30% was the annual bonus target for Hayward, Alexander Rosén, and Silva under their employment agreements.
- No performance-based stock options have been granted to date, although the board reserves discretion to grant them.
Other Jupiter Neurosciences proxy statements
- 2025 proxy statement
Christer Rosén paid $154,076 (-89% on the year).
Filed Nov 06, 2025
About this page
Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.